Regulation of the Arf tumor suppressor in Eμ-Myc transgenic mice: Longitudinal study of Myc-induced lymphomagenesis

Blood

Volumn 109, Issue 2, 2007, Pages 792-794

  Bertwistle, David ^a   Sherr, Charles J ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; GREEN FLUORESCENT PROTEIN; MYC PROTEIN; PROTEIN P19; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ALLELE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DISEASE COURSE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE;

EID: 33846214693     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-033985     Document Type: Article

References (18)

1. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta Rev Cancer. 1998;1378:F115-F177.
2. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103-112.
3. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003;13:77-83.
4. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658-2669.
5. Jacobs JJL, Scheijen B, Vonchen J-W, et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc induced apoptosis via INK4a/ARF. Genes Dev. 1999;13:2678-2690.
6. Schmitt CA, McCurrach ME, De Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13:2670-2677.
7. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533-538.
8. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986;47:11-18.
9. Harris AW, Pinkert CA, Crawford M, et al. The E mu-myc transgenic mouse: a model for high incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167:353-371.
10. Arf tumor suppressor protein. Hybrid Hybridomics. 2004;23:293-300.
11. Zindy F, Williams RT, Baudino TA, et al. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A. 2003;100:15930-15935.
12. Baudino TA, Maclean KH, Brennan J, et al. Mycmediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell. 2003;11:905-914.
13. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 1999;59:1685s-1692s.
14. Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21:5063-5070.
15. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22:9007-9021.
16. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:787-789.
17. Lowe SW, Cepero E, Evan G. Intrinsic tumor suppression. Nature. 2004;432:307-315.
18. Jacobsen KA, Prasad VS, Sidman CL, Osmond DG. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of Eμ-myc transgenic mice. Blood. 1994;84:2784-2794.